1. COVID-19-associated pulmonary aspergillosis (CAPA) in hematological patients: Could antifungal prophylaxis be necessary? A nationwide study
- Author
-
Álvaro Tamayo-Velasco, Rocío López-Herrero, Lara María Gómez-García, Laura Sánchez-de Prada, Gerardo Aguilar-Monserrate, Marta Martín-Fernández, Miguel Bardají-Carrillo, Alejandro Álvaro-Meca, Eduardo Tamayo, Salvador Resino, José Pablo Miramontes-González, and María Jesús Peñarrubia-Ponce
- Subjects
COVID-19-associated pulmonary aspergillosis (CAPA) ,Immunosuppressed infections, hematological patients ,SARS-CoV-2 ,Fungal infections ,Antifungal prophylaxis ,Infectious and parasitic diseases ,RC109-216 ,Public aspects of medicine ,RA1-1270 - Abstract
Background: COVID-19-associated pulmonary aspergillosis (CAPA) has emerged as a relatively common complication. Multiple studies described this relationship in critical patients, however its incidence and outcome in other risk groups such as immunosuppressed patients remains unknown. In this sense, we aimed to evaluate the rates and outcomes of CAPA in hematological patients and according to the different hematological malignances, comparing to invasive pulmonary aspergillosis (IPA) in non-COVID-19 ones. Methods: Nationwide, population-based and retrospective observational cohort study including all adult patients with hematological malignancies admitted in Spain since March 1, 2020 to December 31, 2021. The main outcome variable was the diagnosis of IPA during hospitalization in hematological patients with or without COVID-19 at admission. The rate of CAPA compared to IPA in non-COVID-19 patients in each hematological malignancy was also performed, as well as survival curve analysis. Findings: COVID-19 was diagnosed in 3.85 % (4367 out of 113,525) of the hematological adult inpatients. COVID-19 group developed more fungal infections (5.1 % vs. 3 %; p
- Published
- 2024
- Full Text
- View/download PDF